192 filings
Page 5 of 10
6-K
7lfbeim1 kulugva
4 Jun 19
Affimed Announces Annual General Meeting of Shareholders
4:16pm
6-K
mdhvh o9lz
22 May 19
Current report (foreign)
7:37am
6-K
5dbgwmjc cslbn
17 Apr 19
Affimed Provides Regulatory Update on AFM11 Clinical Program
4:10pm
6-K
fahvhchf9938mu1
7 Jan 19
Actualizing the Untapped Potential of the Innate Immune System Affimed’s Approach to Advancing Immuno - oncology January 2019
7:01am
424B5
gfjrlfb2siz0ibadhh
8 Nov 18
Prospectus supplement for primary offering
4:31pm
EFFECT
hdoqtp6e v4
8 Nov 18
Notice of effectiveness
12:15am
6-K
2xch zys6sdldxrj34qr
7 Nov 18
Condensed Consolidated Financial Statements
7:31am
UPLOAD
e7vmo
6 Nov 18
Letter from SEC
12:00am
CORRESP
04p2j
5 Nov 18
Correspondence with SEC
12:00am
6-K
odt3x6
1 Nov 18
Affimed Announces Oral Presentation and Five Poster Presentations at the 2018 American Society of Hematology Annual Meeting
9:20am
F-3
jlih5lgh22ctpumx
22 Oct 18
Shelf registration (foreign)
4:32pm
6-K/A
qwvepbipd0cd8rfzh7
16 Oct 18
Current report (foreign) (amended)
4:30pm
6-K
scg9es7fg 63f
9 Oct 18
Affimed Places AFM11 (CD19/CD3-Targeting T cell Engager) Phase 1 Program on Clinical Hold
6:05am
CT ORDER
j0eo zqf5im
17 Sep 18
Confidential treatment order
12:00am
6-K
ewt96
27 Aug 18
Current report (foreign)
12:00am
6-K
lmuvcx0ckx8c7n1hg0
8 Aug 18
Index to Condensed Consolidated Financial Statements
7:30am
6-K
f5o nqkselxcj
20 Jun 18
Current report (foreign)
4:15pm
6-K
0yyim1bvm9gxev
15 Jun 18
Current report (foreign)
12:00am
6-K
y8quz4dsygqk694z6p7e
18 May 18
Affimed Announces Annual General Meeting of Shareholders
4:17pm